Lupin Recalls Over 51,000 Antibiotic Bottles in US Due to Defective Containers

Drug firm Lupin is recalling over 51,000 bottles of Cefdinir for Oral Suspension in the US market due to a defective container issue, as reported by the USFDA. The recall of this generic antibiotic, manufactured at Lupin's Mandideep plant, was initiated voluntarily on May 8.

In a significant development, drug firm Lupin has announced the recall of over 51,000 bottles of its generic antibiotic Cefdinir for Oral Suspension from the US market. The recall, initiated due to defective containers lacking seal integrity, has raised concerns over quality control measures.

According to the US Food and Drug Administration (USFDA), the Baltimore-based arm of Lupin commenced the Class II recall for 51,006 bottles of the medication on May 8. A Class II recall typically occurs when there is a potential for temporary or medically reversible adverse health consequences.

Notably, the affected batch was manufactured at Lupin's plant in Mandideep, India, a nation that supplies around 20% of the global demand for generic medicines. While the quality mishap impacts the drug firm's reputation, it underscores the ongoing need for stringent quality control in pharmaceutical manufacturing.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)